MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526792 | Name: SDZ-220-581

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SDZ-220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease.

Chemical Structure

SDZ-220-581
SDZ-220-581
CAS#174575-17-8 (free)

Theoretical Analysis

MedKoo Cat#: 526792

Name: SDZ-220-581

CAS#: 174575-17-8 (free)

Chemical Formula: C16H17ClNO5P

Exact Mass: 369.0533

Molecular Weight: 369.74

Elemental Analysis: C, 51.98; H, 4.63; Cl, 9.59; N, 3.79; O, 21.64; P, 8.38

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SDZ-220-581; SDZ 220-581; SDZ220-581. SDZ-220581; SDZ 220581; SDZ220581.
IUPAC/Chemical Name
(S)-2-amino-3-(2'-chloro-5-(phosphonomethyl)-[1,1'-biphenyl]-3-yl)propanoic acid
InChi Key
InChi Code
SMILES Code
O=C(O)[C@@H](N)CC1=CC(C2=CC=CC=C2Cl)=CC(CP(O)(O)=O)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
More Info
Related CAS# 174575-17-8 (free) 179411-94-0 (ammonium).

Preparing Stock Solutions

The following data is based on the product molecular weight 369.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gilmour G, Broad LM, Wafford KA, Britton T, Colvin EM, Fivush A, Gastambide F, Getman B, Heinz BA, McCarthy AP, Prieto L, Shanks E, Smith JW, Taboada L, Edgar DM, Tricklebank MD. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39. doi: 10.1016/j.neuropharm.2012.07.030. Epub 2012 Aug 1. PubMed PMID: 22884720. 2: Gastambide F, Gilmour G, Robbins TW, Tricklebank MD. The mGlu₅ positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology. 2013 Jan;64:240-7. doi: 10.1016/j.neuropharm.2012.07.039. Epub 2012 Aug 1. PubMed PMID: 22884612. 3: Phillips KG, Cotel MC, McCarthy AP, Edgar DM, Tricklebank M, O'Neill MJ, Jones MW, Wafford KA. Differential effects of NMDA antagonists on high frequency and gamma EEG oscillations in a neurodevelopmental model of schizophrenia. Neuropharmacology. 2012 Mar;62(3):1359-70. doi: 10.1016/j.neuropharm.2011.04.006. Epub 2011 Apr 19. PubMed PMID: 21521646. 4: Smith JW, Gastambide F, Gilmour G, Dix S, Foss J, Lloyd K, Malik N, Tricklebank M. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl). 2011 Sep;217(2):255-69. doi: 10.1007/s00213-011-2277-5. Epub 2011 Apr 12. PubMed PMID: 21484239. 5: Zhang M, Ballard ME, Basso AM, Bratcher N, Browman KE, Curzon P, Konno R, Meyer AH, Rueter LE. Behavioral characterization of a mutant mouse strain lacking D-amino acid oxidase activity. Behav Brain Res. 2011 Feb 2;217(1):81-7. doi: 10.1016/j.bbr.2010.09.030. Epub 2010 Oct 7. PubMed PMID: 20933022. 6: Canning BJ, Mori N. Encoding of the cough reflex in anesthetized guinea pigs. Am J Physiol Regul Integr Comp Physiol. 2011 Feb;300(2):R369-77. doi: 10.1152/ajpregu.00044.2010. Epub 2010 Oct 6. PubMed PMID: 20926760; PubMed Central PMCID: PMC3043807. 7: Linderholm K, Powell S, Olsson E, Holtze M, Snodgrass R, Erhardt S. Role of the NMDA-receptor in Prepulse Inhibition in the Rat. Int J Tryptophan Res. 2010;3:1-12. Epub 2010 Feb 12. PubMed PMID: 22084584; PubMed Central PMCID: PMC3195246. 8: Gilmour G, Pioli EY, Dix SL, Smith JW, Conway MW, Jones WT, Loomis S, Mason R, Shahabi S, Tricklebank MD. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology (Berl). 2009 Aug;205(2):203-16. doi: 10.1007/s00213-009-1530-7. Epub 2009 May 7. PubMed PMID: 19421743. 9: Hellier JL, White A, Williams PA, Dudek FE, Staley KJ. NMDA receptor-mediated long-term alterations in epileptiform activity in experimental chronic epilepsy. Neuropharmacology. 2009 Feb;56(2):414-21. doi: 10.1016/j.neuropharm.2008.09.009. Epub 2008 Oct 7. PubMed PMID: 18930747; PubMed Central PMCID: PMC2698817. 10: Linderholm KR, Andersson A, Olsson S, Olsson E, Snodgrass R, Engberg G, Erhardt S. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology. 2007 Dec;53(8):918-24. Epub 2007 Sep 20. PubMed PMID: 17959203. 11: Hellier JL, Grosshans DR, Coultrap SJ, Jones JP, Dobelis P, Browning MD, Staley KJ. NMDA receptor trafficking at recurrent synapses stabilizes the state of the CA3 network. J Neurophysiol. 2007 Nov;98(5):2818-26. Epub 2007 Aug 29. PubMed PMID: 17728388. 12: Chaperon F, Müller W, Auberson YP, Tricklebank MD, Neijt HC. Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol. 2003 Sep;14(5-6):477-87. PubMed PMID: 14501261. 13: Chen C, Blitz DM, Regehr WG. Contributions of receptor desensitization and saturation to plasticity at the retinogeniculate synapse. Neuron. 2002 Feb 28;33(5):779-88. PubMed PMID: 11879654. 14: Bakshi VP, Tricklebank M, Neijt HC, Lehmann-Masten V, Geyer MA. Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats. J Pharmacol Exp Ther. 1999 Feb;288(2):643-52. PubMed PMID: 9918570. 15: Bespalov AY, Beardsley PM, Balster RL. Interactions between N-methyl-D-aspartate receptor antagonists and the discriminative stimulus effects of morphine in rats. Pharmacol Biochem Behav. 1998 Jun;60(2):507-17. PubMed PMID: 9632234. 16: McAllister KH. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. Eur J Pharmacol. 1996 Oct 31;314(3):307-11. PubMed PMID: 8957251. 17: Urwyler S, Campbell E, Fricker G, Jenner P, Lemaire M, McAllister KH, Neijt HC, Park CK, Perkins M, Rudin M, Sauter A, Smith L, Wiederhold KH, Müller W. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):655-69. PubMed PMID: 8887975.